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1547-5271 B 2015 Heart Rhythm Society.Open access under CC BY-NC-ND license.OBJECTIVE We aimed to determine the role of new-generation
atrial antitachycardia pacing (Reactive ATP) in preventing AF
disease progression.
METHODS Patients with dual-chamber pacemaker and with
previous atrial tachyarrhythmias were randomly assigned to DDDR
(n¼ 385 (33%)), MVP (n¼ 398 (34%)), or DDDRPþMVP (n¼ 383
(33%)) group. The incidence of permanent AF, as deﬁned by the
study investigator, or persistent AF, deﬁned as Z7 consecutive
days with AF, was estimated using the Kaplan-Meier method,
while its association with patients’ characteristics was evaluated
via multivariable Cox regression.
RESULTS At 2 years, the incidence of permanent or persistent AF
was 26% (95% conﬁdence interval [CI] 22%–31%) in the DDDR
group, 25% (95% CI 21%–30%) in the MVP group, and 15% (95%
CI 12%–20%) in the DDDRPþMVP group (P o .001 vs DDDR; P ¼
.002 vs MVP). Generalized estimating equation–adjusted Reactive
ATP efﬁcacy was 44.4% (95% CI 41.3%–47.6%). Multivariate
modeling identiﬁed high Reactive ATP efﬁcacy (444.4%) as a
signiﬁcant predictor of reduced permanent or persistent AF risk
(hazard ratio 0.32; 95% CI 0.13–0.781; P ¼ .012) and episodes’
characteristics, such as long atrial arrhythmia cycle length,
regularity, and the number of rhythm transitions, as predictors
of high ATP efﬁcacy.
CONCLUSION In patients with bradycardia, DDDRPþMVP delays AF
disease progression, with Reactive ATP efﬁcacy being an independ-
ent predictor of permanent or persistent AF reduction.http://dx.doi.org/10.1016/j.hrthm.2015.04.015
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Atrial ﬁbrillation (AF), which is recognized as a cause of
mortality, morbidity, and quality-of-life impairment, is the
most common sustained cardiac arrhythmia encountered in
clinical practice, and its incidence is increasing rapidly
worldwide.1 Atrial tachyarrhythmias, which comprise AF,
atrial ﬂutters, and atrial tachycardias, are frequent comorbid-
ities in patients with indications for implantable cardiac
devices.1–6 Reentrant atrial tachyarrhythmias are susceptible
to termination by means of atrial antitachycardia pacing
(ATP).7–10 Accordingly, some dual-chamber pacemakers
and deﬁbrillators incorporate suites of atrial ATP therapies
that are automatically applied on detection of atrial tachyar-
rhythmias. The efﬁcacy of atrial ATP in terminating atrial
tachyarrhythmias has been measured in a range between
30% and 60%.5–10 Although high ATP efﬁcacy has been
associated with a reduction in atrial tachyarrhythmias burden
over time,9 the clinical impact of atrial ATP has not been
reliably demonstrated in randomized clinical trials.5,6,8 The
MINimizE Right Ventricular pacing to prevent Atrial
ﬁbrillation and heart failure (MINERVA) randomized trial11
was designed to investigate the effect of a combination of
atrial preventive pacing and atrial ATP (DDDRP), and
managed ventricular pacing (MVP), a pacing mode designed
to give priority to intrinsic ventricular activation, thereby
minimizing the adverse effects of unnecessary right ven-
tricular pacing.12–14 The main results of the trial15 show that
this combination of algorithms was associated with a statisti-
cally and clinically signiﬁcant 61% lower risk of progression
to permanent AF on 2-year follow-up in patients with
bradycardia and paroxysmal or persistent atrial tachyar-
rhythmias when compared with standard dual-chamber
pacing (DDDR). The prespeciﬁed secondary analysis of
the MINERVA study, which is reported here, aimed to
determine the relationship between AF progression and
efﬁcacy of Reactive ATP. The latter is a new-generation
atrial ATP that attempts termination of atrial tachyarrhyth-
mias at onset and after any change in rate or regularity when
the episode may be most amenable to termination by pacing.
Methods
Study design, patient population, and follow-up
The details of the MINERVA study design have already been
provided.11,15 In brief, the MINERVA trial was a multicenter,
randomized, single-blind, controlled trial involving 63 cardiol-
ogy centers in 15 countries, as listed in the Online Supplemental
Appendix. The study was approved by the ethics committees of
all participating centers and was conducted in compliance withthe Declaration of Helsinki. All patients provided written
informed consent. Inclusion criteria were standard indications
for permanent DDDR and a history of AF, atrial ﬂutter, or atrial
tachycardia (at least 1 documented episode in the last 12
months). The main exclusion criteria were history of permanent
AF, third-degree atrioventricular (AV) block, or history of AV
node ablation or AF ablation. After implantation of bipolar leads
in the right atrium and ventricle and of a dual-chamber
pacemaker (EnRhythm, Medtronic Inc, Minneapolis, MN),
eligible patients were randomly assigned in a 1:1:1 manner to
(1) standard DDDR (control DDDR group), (2) atrial preventive
pacing, atrial ATP, and MVP (DDDRPþMVP group), and (3)
DDDR with MVP (MVP group) (Figure 1). Patients underwent
follow-up examination in their respective therapy groups 3 and 6
months after implantation and thereafter every 6 months until
the last enrolled patient had reached 2 years of observation.
Reactive ATP
The EnRhythm pacemaker can respond to a sustained atrial
tachyarrhythmia by delivering atrial ATP therapy, which can
be programmed as a Ramp, a series of pacing stimuli
delivered at decreasing intervals, or as a Burstþ, a series
of pulses followed by 2 premature stimuli.
The new-generation atrial ATP, Reactive ATP, monitors the
atrial rhythm within an atrial tachyarrhythmia detection zone,
which is subdivided into subzones; speciﬁcally selecting an
atrial tachyarrhythmia interval of 400 ms, the atrial tachyar-
rhythmia zone, comprised between 100 and 400 ms, is divided
into six 50 ms subzones for regular rhythms and into three 100
ms subzones for irregular rhythms. Each subzone is supplied
with a separate set of atrial ATP therapies that were 10 Ramp
sequences, 10 Burstþ sequences, and 10 Ramp sequences in the
MINERVA trial. If the rhythm shifts into a different subzone
because of a change in cycle length or regularity, the device
delivers therapies from those available in the new subzone.
Analysis objectives, end points, and design
The main objective of this prespeciﬁed secondary analysis of
the MINERVA study was to evaluate the relationship
between Reactive ATP efﬁcacy and AF progression.
The main end point of the analysis reported was time to
ﬁrst permanent or persistent AF. The deﬁnition of permanent
AF was based on clinical assessment by the center inves-
tigator (long AF duration coupled with decision not to
cardiovert the patient) and required AF to be documented
during 2 consecutive follow-up visits, which, as per study
design, were separated by at least 3 months. This end point
was adjudicated by an independent event adjudicationC BY-NC-ND license.
Figure 1 Study ﬂowchart. AF ¼ atrial ﬁbrillation; AT ¼ atrial tachyarrhythmia; ATP ¼ antitachycardia pacing; DDDR ¼ dual-chamber pacing; DDDRP ¼
atrial preventive pacing and atrial antitachycardia pacing; MVP ¼ managed ventricular pacing.
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deﬁned as at least 7 consecutive days with 22 hours of
device-recorded AF per day or at least 1 day with an episode
of AF lasting at least 22 hours that was interrupted with an
electrical or chemical cardioversion.
Secondary end points were ATP efﬁcacy, atrial tachyar-
rhythmia cycle length, deﬁned as the median of 12 atrial
cycle lengths, atrial pacing percentage, ventricular pacing
percentage, atrial tachyarrhythmia regularity (an episode was
deﬁned as regular if, on ordering the last 12 atrial intervals as
a function of cycle length and ignoring the smallest and the
largest ones, the difference between the 2nd and the 11th
intervals on the list was o25% of the median atrial cycle
length), and number of rate and regularity transitions that
occurred during an atrial tachyarrhythmia episode (a tran-
sition being a jump from one to another of the described
atrial tachyarrhythmia detection subzones).
Time to ﬁrst permanent or persistent AF was ﬁrst evaluated
in the 3 randomized cohorts by considering as time zero the
day of randomization. In order to evaluate the association
between permanent or persistent AF occurrence and ATP
efﬁcacy, a second analysis considered a run-in period of 6
months after randomization. Each patient with tachyarrhyth-
mia episodes in the ﬁrst 6 months was characterized by
baseline values for ATP efﬁcacy and other device-detected
variables, such as tachyarrhythmia cycle length, atrial pacing,
and ventricular pacing, as estimated in this run-in period. The
development of permanent or persistent AF was then eval-
uated after the run-in period. In this way, the patients’ baseline
characteristics, both clinical and device-derived ones, possiblepredictors, and permanent or persistent AF occurrence, the
outcome, were derived from independent time intervals.
DDDRPþMVP patients were then divided into 2 cohorts—
high or low ATP efﬁcacy—according to the fact that their
ATP efﬁcacy was greater or lower than the median ATP
efﬁcacy estimated in the overall DDDRPþMVP patient
population. The selection of DDDRPþMVP patients on the
basis of their ATP efﬁcacy induced automatically the selection
of patients with atrial tachyarrhythmia episodes longer than 2
minutes, since the time required for episode detection is about
1 minute and because ATP delivery was programmed after 1
minute of sustained arrhythmia. Consequently, the risk of
permanent or persistent AF was evaluated in 4 patients’
subgroups: 239 DDDRPþMVP patients with treated episodes
(121 in the low ATP efﬁcacy group and 118 in the high ATP
efﬁcacy group), and 268 patients in the MVP group and 280
patients in the control DDDR group, who had atrial tachyar-
rhythmias longer than 2 minutes.Statistical analysis
The analysis set included all the patients randomized,
according to the intention-to-treat principle, and data
throughout the 2-year follow-up period.
Continuous data were described as means and SDs or as
median and interquartile range (IQR), as appropriate; cate-
gorical data were expressed as counts and percentages.
Homogeneity of baseline characteristics was assessed by
using the t test or Wilcoxon test for continuous variables, as
appropriate, and the χ2 test for categorical variables.
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efﬁcacy was adjusted by means of the generalized estimating
equation (GEE) method. Logistic regression was used to
evaluate the association between ATP efﬁcacy and patients’ or
episodes’ characteristics, and the odds ratios together with
their 95% conﬁdence intervals (CIs) were reported.
To analyze the time to ﬁrst permanent or persistent AF, the
Kaplan-Meier method was used and cumulative hazard curves
were compared by means of the log-rank test. The risk of
permanent or persistent AF was evaluated using the Cox
proportional hazards regression model, and hazard ratios
(HRs) with 95% CIs were computed to compare risk proﬁles.
All variables that were signiﬁcant at the .10 level were further
analyzed in a multivariable backward elimination model. The
proportional hazard assumptions were tested by using Schoen-
feld residuals. All tests were 2-sided, and a P value of o.05
was considered to indicate statistical signiﬁcance. SAS 9.3
(SAS Institute Inc, Cary, NC) was used for statistical analyses.Results
A total of 1166 patients were randomized and followed up,
as shown in Figure 1. The baseline characteristics of the 1166
patients have already been described.15 At baseline, 982
patients (86%) had a history of AF, 228 (20%) had a history
of atrial ﬂutter, and 197 (17%) had a history of atrial
tachycardia. As described previously,15 the median ventric-
ular pacing percentage was 2% (25th–75th percentile 0%–
11%) in the DDDRPþMVP group, 1% (25th–75th percen-
tile 0%–9%) in the MVP group, and 53% (25th–75th
percentile 15%–84%) in control DDDR group (P o .001
vs MVP and vs DDDRPþMVP).AF occurrence and cycle length
Within 2 years of follow-up, 804 patients suffered AF longer
than 5 minutes, speciﬁcally 269 (69.9%) in the control DDDR
arm, 273 (68.6%) in the MVP arm (P ¼ .689 vs control
DDDR), and 262 (68.4%) in the DDDRPþMVP arm (P¼ .571
vs control DDDR; P = .856 vs MVP). The median AF burden
was 17 min/d in control DDDR patients, 9 min/d in MVP
patients, and 4 min/d in DDDRPþMVP patients (P ¼ .002 vs
control DDDR; P ¼ .032 vs MVP). The median atrial cycle
length at onset, as measured for the 89,411 atrial tachyarrhyth-
mia episodes saved in device diagnostics with complete data,
was 246 ms (IQR 214–278 ms), which corresponds to a median
rate of 244 beats/min (IQR 216–280 beats/min).Permanent or persistent AF
At 2 years, permanent or persistent AF occurred in 222 of
1166 patients (19.0%), speciﬁcally in 91 (actuarial incidence
26.2%; 95% CI 21.8%–31.2%) patients in the control DDDR
arm, 83 (actuarial incidence 25.0%; 95% CI 20.6%–30.1%)
patients in the MVP arm, and 48 (actuarial incidence 15.1%;
95% CI 11.6%–19.6%) patients in the DDDRPþMVP arm
(HR 0.52; 95% CI 0.36–0.73; P o .001 vs control DDDR;
HR 0.57; 95% CI 0.40–0.81; P ¼ .002 vs MVP).Reactive ATP efﬁcacy and its association with
permanent or persistent AF
In the DDDRPþMVP arm, 25,639 atrial tachyarrhythmia
episodes longer than 2 minutes were treated by ATP in 239
patients, and the generalized estimating equation–adjusted
Reactive ATP efﬁcacy was 44.4% (95% CI 41.3%–47.6%).
These patients were compared with 280 control DDDR and 268
MVP patients who suffered atrial tachyarrhythmia episodes
longer than 2 minutes. Table 1 lists baseline characteristics of
these patient subgroups and of DDDRPþMVP patients divided
in 2 subgroups: low ATP efﬁcacy patients (r44.4%) and high
ATP efﬁcacy patients (444.4%). In these patient subgroups,
the actuarial incidence of permanent or persistent AF at 2 years
(Figure 2) was 33.6% (95% CI 28.2%–39.7%) in the control
DDDR group, 30.6% (95% CI 25.1%–36.9%) in the MVP
group, 27.9% (95% CI 20.5%–37.4%) in the DDDRPþMVP–
low ATP efﬁcacy group (log-rank test, P ¼ .0475 vs control
DDDR; P ¼ .3121 vs MVP), and 13.5% (95% CI 8.2%–
21.8%) in the DDDRPþMVP–high ATP efﬁcacy group (log-
rank test, Po .001 vs control DDDR, P¼ .0197 vs MVP, and
P ¼ .0315 vs DDDRPþMVP–low ATP efﬁcacy).
Table 2 shows the univariate and multivariate association
between permanent or persistent AF and patients’ characteristics
in the DDDRPþMVP arm. In particular, permanent or persis-
tent AF risk was signiﬁcantly reduced in patients with high
Reactive ATP efﬁcacy (444.4%) (HR 0.32; 95%CI 0.13–0.78;
P ¼ .012) and in patients with high atrial pacing (HR 0.98 [ie,
2% risk decrease for each 1% increase in atrial pacing]; 95% CI
0.97–0.99; P¼ .011); conversely, a higher risk of permanent or
persistent AF was associated with patients with higher ven-
tricular pacing (HR 1.03 [ie, 3% risk increase for each 1%
increase in ventricular pacing]; 95% CI 1.02–1.05; Po .001).Predictors of ATP efﬁcacy
Univariate and multivariate logistic regression analyses
showed that Reactive ATP efﬁcacy was associated with
episodes’ characteristics such as atrial tachyarrhythmia cycle
length and regularity at last ATP attempt and number of atrial
tachyarrhythmia rhythm transitions, as described in Table 3.
Of the 19,143 episodes with complete diagnostic data,
12,214 episodes (64%) were treated in 2 or more atrial
tachyarrhythmia detection subzones, showing rate or regu-
larity transitions. Importantly, the mean number of detection
subzones in which episodes were treated was 1.5  0.7, 2.4
 0.9, 2.9  1.0, 3.7  1.2, and 4.5  1.4 for episodes’
durations comprised between 2 and 15 minutes, between 15
and 30 minutes, between 30 and 60 minutes, between 1 and 6
hours, and46 hours, respectively, showing signiﬁcant (Po
.001) increase as a function of episode duration.
Figure 3 shows the sequence of Reactive ATP attempts
(panel A) and the interval plot (panel B) for a speciﬁc episode
that started fast and irregular, underwent through 24 rate or
regularity transitions, and ﬁnally became regular and slower and
was terminated, after 8.5 hours, at the 63th Reactive ATP
attempt, by the second Reactive ATP attempt in the regular atrial
tachyarrhythmia window comprised between 300 and 350 ms.
Table 1 Demographic characteristics, medical history, and pacemaker indications
Characteristic
Control DDDR
(280 patients)
MVP
(268 patients)
DDDRPþMVP
(239 patients)
DDDRPþMVP low ATP
efﬁcacy (121 patients)
DDDRPþMVP high ATP
efﬁcacy (118 patients)
P (low vs high
ATP efﬁcacy)
Demographic characteristics
Sex: male 146 (52.1) 131 (48.9) 104 (43.5) 51 (42.1) 53 (44.9) .666
Age (y) 73  9 74  8 74  9 73  9 74  9 .504
Medical history
Previous atrial tachyarrhythmia 280 (100.0) 268 (100.0) 239 (100.0) 121 (100.0) 118 (100.0)
Atrial ﬁbrillation 251 (90.9) 237 (89.8) 207 (87.3) 105 (87.5) 102 (87.2) .941
Atrial ﬂutter 45 (16.9) 62 (23.8) 47 (20.4) 22 (18.5) 25 (22.5) .448
Atrial tachycardia 36 (13.4) 41 (15.8) 42 (18.1) 21 (17.6) 21 (18.6) .853
Persistent atrial tachyarrhythmia 33 (12.3) 28 (10.7) 19 (8.3) 11 (9.4) 8 (7.1) .815
Paroxysmal atrial tachyarrhythmia 206 (76.9) 205 (78.2) 181 (78.7) 91 (77.8) 90 (79.7)
Both paroxysmal and persistent atrial tachyarrhythmia 29 (10.8) 29 (11.1) 30 (13.0) 15 (12.8) 15 (13.3)
Atrial cardioversions 67 (25.2) 73 (28.0) 63 (27.0) 37 (30.8) 26 (23.0) .179
Hypertension 182 (68.4) 187 (71.4) 172 (74.8) 91 (76.5) 81 (73.0) .542
Previous stroke/TIA 30 (10.8) 27 (10.2) 26 (11.1) 16 (13.2) 10 (8.8) .277
Diabetes 53 (19.7) 42 (15.9) 30 (13.0) 18 (15.1) 12 (10.8) .332
NYHA class 4 II 18 (6.4) 10 (3.7) 5 (2.1) 4 (4.0) 1 (1.1) .201
LVEF (%) 57  9 57  10 57  9 56  10 59  10 .325
PR interval (ms) 180 (160–210) 189 (160–210) 180 (160–200) 180 (156–200) 180 (160–200) .665
CHADS2 score 1.7 (1  2) 1.7  1.2 1.7  1.1 1.7  1.1 1.7  1. 1 .911
Baseline medications
Anticoagulants 141 (50.4) 129 (48.3) 109 (45.8) 60 (50.0) 49 (41.5) .190
Antiplatelet 93 (33.2) 101 (37.8) 100 (42.0) 51 (42.5) 49 (41.5) .879
Antiarrhythmic drugs class III 93 (33.2) 83 (31.1) 71 (29.8) 30 (24.8) 41 (34.7) .100
Antiarrhythmic drugs class IC 45 (16.1) 52 (19.5) 50 (21.0) 23 (19.2) 27 (22.9) .482
Pacemaker indications
Sinus node disease 241 (86.1) 228 (85.1) 200 (83.7) 99 (81.8) 101 (85.6) .810
First- or second-degree AV block 18 (6.4) 14 (5.2) 15 (6.3) 9 (7.4) 6 (5.1)
Transient complete AV block 4 (1.4%) 8 (3.0) 3 (1.3) 2 (1.7) 1 (0.8)
Other 17 (6.1) 18 (6.7) 21 (8.8) 11 (9.1) 10 (8.5)
Values are presented as mean  SD, as n (%), or as median (Q1–Q3).
No variable showed signiﬁcant differences either among the 3 randomized groups (control DDDR, MVP, or DDDRPþMVP) or between DDDRPþMVP–low ATP efﬁcacy and DDDRPþMVP–high ATP efﬁcacy groups.
ATP ¼ antitachycardia pacing; AV ¼ atrioventricular; DDDR ¼ dual-chamber pacing; DDDRP ¼ atrial preventive pacing and atrial antitachycardia pacing; LVEF ¼ left ventricle ejection fraction; MVP ¼ minimal
ventricular pacing; NYHA ¼ New York Heart Association; Q1–Q3 ¼ ﬁrst and third quartiles; TIA ¼ transient ischemic attack.
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Figure 2 Incidence of permanent or persistent AF in the control DDDR arm, in the MVP arm, and in the DDDRPþMVP arm, which was divided into 2
subgroups—low and high ATP efﬁcacy—as a function of the Reactive ATP efﬁcacy. AF ¼ atrial ﬁbrillation; ATP ¼ antitachycardia pacing; DDDR ¼ dual-
chamber pacing; DDDRP ¼ atrial preventive pacing and atrial antitachycardia pacing; MVP ¼ managed ventricular pacing.
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The main results of our analysis show that high efﬁcacy
Reactive ATP is associated with a reduction in the risk of
permanent or persistent AF (Figure 2 and Table 2). The
progression of atrial disease seems to be prevented or delayed
through termination of atrial tachyarrhythmia episodes when
they are slow and regular, a condition that can be observed at
the onset of the episode or over time; indeed, we observed that
long atrial tachyarrhythmia episodes undergo many rhythm
transitions, becoming amenable to ATP termination. TheseTable 2 Univariate and multivariate models for the risk of permanent
Parameter
Univariate model
HR (95% CI)
Sex: male 1.04 (0.49–2.22)
Age 1.00 (0.96–1.05)
Persistent AF 1.34 (0.54–3.31)
Cardioversions 2.54 (1.19–5.43)
Hypertension 1.04 (0.44–2.45)
Stroke/TIA 1.29 (0.45–3.71)
Diabetes 1.22 (0.37–4.06)
History of AF hospitalization 2.30 (1.07–4.91)
LVEF 0.97 (0.91–1.02)
Spontaneous PR interval 4180 ms 1.00 (0.99–1.01)
Anticoagulants 2.00 (0.93–4.27)
Antiplatelets 0.47 (0.21–1.08)
Antiarrhythmic drugs class III 0.59 (0.24–1.47)
Antiarrhythmic drugs class IC 0.69 (0.26–1.82)
Mean cycle length* 4246 ms 0.86 (0.38–1.95)
Mean ventricular pacing* 1.04 (1.02–1.05)
Mean atrial pacing* 0.98 (0.97–0.99)
ATP efﬁcacy*444.4% 0.38 (0.17–0.87)
AF ¼ atrial ﬁbrillation; ATP ¼ antitachycardia pacing; CI ¼ conﬁdence interva
York Heart Association; TIA ¼ transient ischemic attack.
*Calculated during the ﬁrst 6 mo of the observation period.results have clinical importance because evolution toward
permanent AF is an important prognostic marker for death,
stroke, or hospital admissions in primary care.16–18 The
Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial16 evaluated
18,201 patients with AF and found that the risk of stroke or
systemic embolism was signiﬁcantly higher in patients with
persistent or permanent AF than in those with paroxysmal AF.
The Atrial Fibrillation in the Barbanza Area Study17,18
identiﬁed progression to permanent AF as a predictor ofor persistent AF
Multivariate model
P HR (95% CI) P
.919
.824
.525
.016 2.33 (1.05–5.02) .038
.926
.642
.747
.032
.250
.387
.074
.074
.259
.454
.716
o.001 1.03 (1.02–1.05) o.001
o.001 0.98 (0.97–0.99) .011
.022 0.32 (0.13–0.78) .012
l; HR ¼ hazard ratio; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New
Table 3 Predictors of ATP efﬁcacy among episodes’ or patients’ baseline characteristics
Parameter
Univariate model* Multivariate model†
Odds ratio (95% CI) P Odds ratio (95% CI) P
Sex: male 1.12 (0.61–2.03) .715
Age 1.01 (0.98–1.04) .384
Persistent AF 1.68 (0.84–3.36) .139
Hypertension 1.12 (0.63–2.00) .697
Stroke/TIA 0.56 (0.18–1.69) .300
Diabetes 1.12 (0.50–2.53) .786
History of AF hospitalization 1.37 (0.74–2.52) .318
NYHA class III-IV 0.70 (0.21–2.36) .567
LVEF 0.98 (0.92–1.05) .598
Spontaneous PR interval 4180 ms 1.84 (0.81–4.16) .146
Anticoagulants 1.01 (0.55–1.83) .980
Antiplatelets 1.16 (0.64–2.13) .620
Antiarrhythmic drugs class III 1.33 (0.71–2.52) .373
Antiarrhythmic drugs class IC 0.58 (0.21–1.60) .295
Long atrial cycle length‡ 3.78 (2.23–6.44) o.001 4.10 (2.32–7.26) o.001
Regular rhythm 1.45 (0.93–2.27) .100 1.72 (1.04–2.86) .035
No. of transitions 1.23 (1.02–1.49) .030
AF ¼ atrial ﬁbrillation; ATP ¼ antitachycardia pacing; CI ¼ conﬁdence interval; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart
Association; TIA ¼ transient ischemic attack.
*Logistic regression model for repeated measures.
†Backward selection method (in: P ¼ .2; out: P ¼ .05).
‡Long atrial arrhythmia cycle length is deﬁned as4210 ms, which was the median of the atrial arrhythmia cycle length at last ATP attempt for the considered
tachyarrhythmias.
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with AF.
As expected, atrial pacing was also associated with lower
risk of permanent or persistent AF and ventricular pacing
with a higher risk of permanent or persistent AF; it is
worthwhile to mention that most DDDRPþMVP patients
had a ventricular pacing percentage very low (median 2%).
Mechanism of the impact of reactive ATP
Although most (86%) of our patients had a history of AF at
baseline and only 20% had a history of atrial ﬂutter and 17% had
a history of atrial tachycardia, many atrial arrhythmia episodes
had quite slow rates at onset, with a median of 244 beats/min, as
estimated by the device. In our patient population, ATP
probably terminated many reentrant atrial tachyarrhythmias.7–10
ATP cannot terminate true AF, but it can terminate atrial
tachyarrhythmia episodes—even if they start fast and irreg-
ular—whenever the rhythm stabilizes and/or slows down.
We observed that many (64%) atrial tachyarrhythmia epi-
sodes underwent rhythm and regularity transitions. Our data
suggest that even after hours of atrial tachyarrhythmia, when
most cardiologists would expect AF to be stably irregular
and fast, transitions toward more regular or slower rhythms
occur, thus making the arrhythmia amenable to ATP termi-
nation (Figure 3). Indeed, we observed that the number of rate
and regularity transitions increased as a function of episode
duration and that ATP efﬁcacy was higher in episodes with
long cycle length, in episodes with many rhythm transitions,
and in episodes with regular rhythm (Table 3).
Before the MINERVA trial, the impact of atrial ATP
therapies was not widely recognized,5,6 since previous studieshad yielded contradictory ﬁndings.8,9 Indeed, the Atrial
Therapy Efﬁcacy and Safety Trial (ATTEST) randomized
parallel trial8 tested atrial preventive and ATP therapies in
368 patients with pacemaker and found no signiﬁcant
reduction in atrial tachyarrhythmia burden or frequency
despite a median ATP efﬁcacy of 54%. Conversely, Gillis
et al9 described a signiﬁcant impact of atrial ATP therapy on
atrial tachyarrhythmia burden in the subgroup of patients with
high ATP efﬁcacy (Z60%). The fact that previous studies on
ATP did not yield convincing results can be explained by the
fact that the devices used in previous trials only featured
standard ATP therapies, which attempt atrial tachyarrhythmia
termination after detection but give up after a maximum of 30
ATP attempts, that is, after about 10–15 minutes. Standard
ATP therapies fail to take advantage of rhythm changes and
are unable to terminate long-lasting atrial tachyarrhythmia.
By contrast, Reactive ATP continues to monitor atrial
rhythm, watches for any change in rate or regularity, and
then opportunistically applies ATP when the episode is most
amenable to termination by pacing. Consequently, Reactive
ATP also treats long episodes and, when effective, prevents
them from being sustained for hours or days.
Clinical implications
The new results reported here of the MINERVA trial for the ﬁrst
time convincingly indicate that Reactive ATP is an effective
means of preventing AF disease progression. Reducing the risk
of persistent and permanent AF have clinical and economic
relevance in terms of improved patient care, by lowering the risk
of stroke and heart failure,16–20 and of reduced health care
resources and costs.15,21 Indeed, the importance of new therapies
Figure 3 Number of Reactive ATP attempts in the atrial tachyarrhythmia detection subzones (A) and interval plot (B) for a speciﬁc atrial tachyarrhythmia
episode that was successfully terminated by Reactive ATP after about 8.5 hours from episode onset. The episode started with an irregular rhythm and a cycle
length of 290 ms and was ﬁrst treated in the irregular atrial tachyarrhythmia window comprised between 200 and 300 ms. After the ﬁrst unsuccessful attempt, the
episode underwent several rate or regularity transitions and was treated in 5 atrial tachyarrhythmia windows, 3 regular windows, and 2 irregular windows.
Finally, the episode transitioned to a regular rhythm and a slower rate, with a cycle length of 330 ms and was terminated at the 63th attempt, in the regular window
comprised between 300 and 350 ms. Panel B shows that the episode was treated by ﬁrst ATP after 1 minute from detection when the episode was irregular and
that after about 8.5 hours the episode became slower and regular, was treated, and terminated within 4 ventricular beats. AF ¼ atrial ﬁbrillation; AT ¼ atrial
tachyarrhythmia; ATP ¼ antitachycardia pacing.
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imately one-third of hospitalizations for cardiac rhythm dis-
turbances and is displaying a clear upward trend worldwide.22–25Study limitations
The study was single blind; therefore, the investigators were
aware of device programming. To limit the possibility to bias
the ascertainment of study end points, permanent AF diag-
noses and cardiovascular hospitalization decisions, performed
by study investigators according to predeﬁned conditions,
were validated by an independent event adjudication commit-
tee on the basis of patients’ data and hospital admissions letters
and according to guidelines. Occurrence of persistent AF was
derived by device diagnostics and therefore by deﬁnition
unbiased by investigator awareness of each patient therapyprogramming. The lower occurrences of atrial cardioversions,
of emergency department visits, and of AF-related hospital-
izations15 in the DDDRPþMVP arm were reassuring about
the fact that investigators did not inﬂuence the study results
and the end point deﬁnition. Findings from the described trial
cannot be generalized for all patients implanted with dual-
chamber pacemakers, but rather to patients included in the
trial, that is, patients with indication to DDDR—but without
complete AV block—and with paroxysmal or persistent atrial
tachyarrhythmias, treated by Reactive ATP.Conclusion
In patients with bradycardia, DDDRPþMVP delays AF
disease progression, with Reactive ATP efﬁcacy being an
independent predictor of permanent or persistent AF risk
1725Padeletti et al Reactive ATP Reduces Risk of Persistent or Permanent AFreduction. While most patients had a history of AF at
baseline, pacemaker diagnostics showed that most atrial
arrhythmias started with relatively long cycle lengths or, over
time, underwent rate or regularity transitions, thus becoming
amenable to termination by pacing. Reactive ATP provides
the opportunity to treat atrial tachyarrhythmias when they
spontaneously organize or slow down.
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This analysis of the MINimizE Right Ventricular pacing to prevent Atrial ﬁbrillation and heart failure clinical trial provides
new evidence about the fact that in patients with history of atrial ﬁbrillation, after pacemaker implant, many atrial
arrhythmias are relatively slow or, over time, undergo rate or regularity transitions. The study results show that the use of a
new atrial antitachycardia pacing (Reactive ATP) prevent the progression of AF to permanent or persistent AF because this
new feature is able to monitor atrial tachyarrhythmias and treat them when they spontaneously organize or slow down, thus
becoming amenable to termination by pacing. Patients with indication to pacing for bradycardia and history of atrial
ﬁbrillation may therefore beneﬁt by a systematic use of atrial antitachycardia pacing.
